Evaluation of the effects of Fampridine (4-aminopyridine) on motor and non-motor symptoms of Parkinson: A randomized double blind trial

Determining the effect of Fampridine (4-aminopyridine) on motor and non-motor symptoms of Parkinson's disease in patients referred to the neurology clinic.

Clinical trial with intervention and control group, with parallel groups, double-blind, randomized, phase 3 on 62 patients. For randomization, block random assignment and the order of assigning each person to each group in a sealed envelope was used.

The study will be conducted on Parkinson patients referred to Shahr-e-Kord Neurology Clinic

Inclusion criteria: known Parkinson's patient (based on symptoms and previous investigations); the presence of Parkinson's symptoms in the patient; the symptoms are not caused by other diseases (such as stroke, trauma, etc.); no interaction with other drugs; no history of seizures. Exit criteria: unwillingness to cooperate; intervention drug interaction with usual drugs; occurrence of drug side effects; intensification of the patient's symptoms; death of the patient history or occurrence of seizures.

One group will receive Fampridine tablets (Cinagen Pharmaceutical Company) as the intervention group, and the other group will receive placebo as the control group, and both groups will receive their standard treatment.

tremor condition; Brady Kinsey's situation; the state of rigidity; sleep disorder condition; Depressive state; state of anxiety; sexual disorder status; sphincter disorder condition; paresthesia condition of organs; Hypotension orthostatic state; General condition of motor and non-motor disorders

In order to start the clinical trial study, with the coordination of the supervisor, 62 patients will be randomly selected from among the patients who meet the entry criteria referring to the neurology clinic, according to the sample size if they meet the entry criteria. Then, people will be assigned to two equal intervention and control groups using the random block allocation method with blocks of 2, 4, and 6, and the order of assigning each person to each group is placed in a sealed envelope based on blocks with a random number. The same number of people are assigned to each of the studied groups

The participants do not know whether they are part of the intervention or control group and do not know whether they are taking medicine or placebo. Medicines and placebos are given to patients by clinical caregivers, and the researcher does not know who received medicine or placebos

The data of the study before and after the intervention are collected and published to check the results of the intervention

The access period starts about 6 months after the publication of the study results

Scientific institutions, students, professors, pharmacists, manufacturing companies

Doctors to use the results of the study in better treatment of the disease Pharmacists for more effort in improving the quality of this drug Professors and students to know more about the effect of this medicine Manufacturing companies to invest in more and better drug production

Mohammad Shams Hafshejani Contact: +989136763428 Email: Mohammadsh3428@gmail.com

After contacting the person with the required information and after confirming the validity of the applicant, the method of obtaining the required information will be announced to the applicant within a few days.